Kirsten Craven

What has the Echo® MS system done for the pharma industry? (And don’t just take our word for it!)

Mar 27, 2023 | Blogs, Discovery, Echo MS, Pharma | 0 comments

Read time: 4 minutes

SCIEX was very proud to have an illustration of the Acoustic Ejection Mass Spectrometry (AEMS) technology that powers the Echo® MS system on the front cover of the Journal of the American Society for Mass Spectrometry in January 2023. The associated article—Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry—was co-authored by scientists from SCIEX and Merck.

According to co-author Chang Liu, Staff Research Scientist at SCIEX, “the results in this work demonstrate high-quality and high-throughput intact protein analysis with the AEMS technology. The platform could be potentially applied widely in drug discovery workflows such as the identification of covalent binders, the ADCs characterizations, and the mAb QC.”¹

This statement raised a question for me: What has the Echo® MS system done for the pharma industry?

How is the Echo® MS system being used?

It didn’t take long for me to find lots of journal articles demonstrating the use of this system in the pharma industry. In a Journal of Pharmaceutical Analysis article, Current status and future directions of high-throughput ADME screening in drug discovery, Wilson Shou of Bristol-Myers Squibb highlighted the importance of HT-ADME screening in drug development and the role mass spectrometry plays. Shou pointed out that high-quality ADME data early in the drug development process reduces attrition later in the development of drug candidates, saving drug companies time and money, and making the treatments patients need available sooner.

Table 2 in the article (reproduced below) shows how well the Echo® MS system can provide high-quality data and save time compared to other commercially available systems.²

Parameters	LC-MS/MS	SPE-MS/MS	LDI-MS	AMI-MS	AE-MS
Speed per well (in seconds)	60 s	10 s	1 s	1 s	1 s
In situ sample cleanup	Yes	Yes	No	No	Yes
Data variability	Low	Low	High	High	Low
Sample format	96/384	96/384	96/384	384	384/1536
Sample volume	>40 µL	>40 µL	<1 µL	<1 µL	<1 µL
Direct analysis	Yes	Yes	No	Yes	Yes

Table 2. Comparison of high-throughput MS analysis approaches. SPE: solid phase extraction; LDI: laser desorption ionization; AMI: acoustic mist ionization; AE: acoustic ejection.

In an SLAS Discovery article, A high-throughput screening assay for mutant isocitrate dehydrogenase 1 using acoustic droplet ejection mass spectrometry, Elisabeth Speckmeier et al. of Sanofi, Integrated Drug Discovery, detailed the development of a method for a mutant IDH1 using the Echo® MS system. The IDH1 gene is of interest because it is found in several types of cancer, such as myelodysplastic syndromes, acute myelogenous leukemia and brain cancer.

According to Speckmeier et al., “we have established a label-free enzymatic assay ADE-MS as a large-scale HTS-capable assay readout. Single-concentration incubations and 57 concentration–response curves showed high reproducibility and analytical performance comparable to the established fluorescence label-based assay readout, but with slightly lower Z-prime and fluctuating S/IC.”³

In another SLAS Discovery article, Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery, Roman P. Simon et al. of Drug Discovery Sciences, Boehringer Ingelheim Pharma, reported on the implementation of a biochemical assay to identify small-molecule inhibitors: cyclic guanosine monophosphate–adenosine monophosphate (GMP-AMP) synthase (cGAS). Simon et al. concluded that “altogether, the established ADE-OPI-MS [Echo® MS system] platform fills in a current technological gap by adding ESI-based MS to the label-free high-throughput readout portfolio.”⁴

What is the Echo® MS system?

The Echo® MS system uses Acoustic Ejection Mass Spectrometry (AEMS). Samples are placed into a well plate that is held in the autosampler of the Echo® MS module and sound energy is applied to the bottom of each well individually. The sound energy causes a reproducible droplet to be ejected from the well, allowing the sample to travel to the Open Port Interface (OPI) before making its way to the source of the mass spectrometer. From this point, the droplet is ionized using electrospray ionization (ESI), and it is ready for detection.

This ejection process has several benefits, including speed and contactless sampling. Combining this approach with mass spectrometry enables speed without compromising on data quality. For a peek at the Echo® MS system in action, watch this video.

References:

¹ Zacharias, AO et al. Ultrahigh-Throughput Intact Protein Analysis with Acoustic Ejection Mass Spectrometry. J. Am. Soc. Mass Spectrom. 2023, 34(1): 4–9. https://doi.org/10.1021/jasms.2c00276

² Shou, WZ. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharm Anal. 2020, 10(3): 201–208. https://doi.org/10.1016/j.jpha.2020.05.004

³ Speckmeier, E et al. A high-throughput screening assay for mutant isocitrate dehydrogenase 1 using acoustic droplet ejection mass spectrometry. SLAS Discov. 2022, 27(5): 298–305. https://doi.org/10.1016/j.slasd.2022.04.002

4 Simon, RP et al. Acoustic Ejection Mass Spectrometry: A Fully Automatable Technology for High-Throughput Screening in Drug Discovery. SLAS Discov. 2021, 26(8): 961–973. https://doi.org/10.1177/24725552211028135

Understanding PFAS and its impact on U.S. drinking water

In recent years, per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a growing topic of interest due to their persistence in the environment and potential health risks. These synthetic compounds have been widely used in various industrial applications and consumer products since the 1940s. PFAS can be found in the air, soil, and water, and studies have shown that most people have detectable levels of PFAS in their bloodstream. One of the main exposure pathways for humans is through drinking water, particularly in communities located near industrial sites, military bases, or areas where firefighting foam has been used.

Selecting an LC-MS system for quantitation of pharmaceutical drug development

We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

Posted by

Kirsten Craven

Kirsten Craven is the Senior Global Marketing Manager for Pharma global strategic marketing at SCIEX. In this role, she manages strategic marketing for the pharmaceutical industry. Kirsten spent the first part of her career working in laboratories across multiple industries before moving into product management, and most recently pharma marketing.

0 Comments